Skip to navigation Skip to content

News

Share

Mouse Study Funded by National MS Society Suggests Laquinimod May Be Capable of Reducing MS Progression

September 23, 2016

An international team administered oral laquinimod – an experimental immune system-modulating treatment under study for progressive MS – to mice, and found that it dramatically reduced inflammation in the meninges, the tissue that encloses the brain. This inflammation has been associated with MS, especially progressive MS. The researchers were funded by the National MS Society and the National Institutes of Health, among others. A clinical trial of laquinimod is currently recruiting 375 people with primary progressive MS. These findings in mice, along with the trial results, will help to determine if laquinimod has potential to become a safe and effective treatment for people with progressive MS, for whom there are few treatment options.

Read more about this study on Medical XPress
Learn about the laquinimod trial in primary progressive MS
The National MS Society is finding solutions for progressive MS – learn how

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system. Symptoms range from numbness and tingling to blindness and paralysis, and there is currently no cure for MS. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. An estimated 1 million people live with MS in the United States. Most people with MS are diagnosed between the ages of 20 and 50, and it affects women three times more than men.

Share


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization and our Identification Number (EIN) is 13-5661935.